Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: The Canadian lamifiban study

Circulation

Volumn 94, Issue 5, 1996, Pages 899-905

  Théroux, Pierre ^a,c   Kouz, Simon ^a   Roy, Louis ^a   Knudtson, Merril L ^a   Diodati, Jean G ^a   Marquis, Jean François ^a   Nasmith, James ^a   Fung, Anthony Y ^a   Boudreault, Jean Rock ^a   Delage, François ^a   Dupuis, Robert ^a   Kells, Catherine ^a   Bokslag, Marianne ^b   Steiner, Beat ^b   Rapold, Hans J ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c MONTREAL HEART INSTITUTE   (Canada)

Author keywords

angina; coronary disease; heparin; lamifiban; platelets

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; LAMIFIBAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; LIGAND BINDING; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVASCULARIZATION; SINGLE BLIND PROCEDURE; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0345553953     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.5.899     Document Type: Article

References (27)

1. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
2. Davies MJ, Thomas AC. Thrombosis and acute coronary-artery lesions in sudden ischemic death. N Engl J Med. 1984;310:1137-1140.
3. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation. 1985;71:699-708.
4. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, 1: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994;308:81-106.
5. Théroux P, Ouimet H, McCans J, Latour J-G, Joly P, Levy G, Pelletier E. Juneau M, Stasiak J, deGuise P, Pelletier GB, Rinzler D, Waters DD. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105-1111.
6. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336:827-830.
7. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, Fox KAA, Chesebro JH, Strain J, Keller C, Kelly A, Lancaster G, Ali J, Kronmal R, Fuster V, and the Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end points analysis from the ATACS trial. Circulation. 1994;89:81-88.
8. Markwardt F, Kaiser B, Novak G. Studies on antithrombotic effects of recombinant hirudin. Thromb Res. 1989;54:377-388.
9. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest. 1985;76:101-108.
10. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553-1559.
11. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:949-955.
12. Alig L, Edenhofer A, Hadvary P, Hürzeler M, Knopp D, Müller M, Steiner B, Trzeciak A, Weller T. Low molecular weight, non-peptide fibrinogen receptor antagonists. J Med Chem. 1992;35:4393-4407.
13. Kouns WC, Kirchhofer D, Hadvary P, Edenhofer A, Weller T, Pfenninger G, Baumgartner HR, Jennings LK, Steiner B. Reversible conformational changes induced in glycoprotein IIb/IIIa by a potent and selective peptidomimetic inhibitor. Blood. 1992;80:2539-2547.
14. Jones CR, Ambros RJ, Rapold HJ, Steiner B, Weller T, Hadvary P. A novel non peptide (GP IIb-IIIa antagonist in man). Thromb Haemost. 1993;69:560. Abstract.
15. Steiner B, Jones CR, Heiningen PWM, Jonkman JHG, Carrol RC, Kouns WC. TRAP-induced ex vivo platelet aggregation might be a useful method to predict anti-thrombotic efficacy. Blood. 1993;82:284a. Abstract.
16. Gold HK, Gimple LW, Yasuda T, Leinbach RC, Werner W, Holt R, Jordan R, Berger H, Collen D, Coller BS. Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest. 1990;86:651-659.
17. Simoons M, de Boer MJ, van den Brand MJBM, van Miltenburg AJM, Hoorntje JCA, Heyndrickx GR, van der Wieken LR, De Bono D, Rutsch W, Schaible TF, Weisman HF, Klootwijk P, Nijssen KM, Stibbe J, de Feyter PJ, and the European Cooperative Study Group. Randomized trial of a GP IIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation. 1994;89:596-603.
18. Schulman SP, Goldschmidt-Clermont PJ, Navetta NC, Chandra HS, Guerci AD, Califf RM, Ferguson JJ, Willerson JT, Wolfe CL, Bahr R, Yakubov SJ, Nygaard TW, Mason SJ, Brashears L, Charo I, du Mée C, Kih MM, Gerstenblith GG. Integrelin in unstable angina: a double-blind randomized trial. Circulation. 1993;88(suppl I):I-608. Abstract.
19. Théroux P, Kleiman N, Shah PK, Williams M, Gill H, Rodriguez S, Niederman A, Broderick GT Jr, Josephson R, Deschenes N, Fitzpat- rick V, Sax FL, for the MK-852 Investigators. A double-blind, heparin-controlled study of MK-852 in unstable angina. Circulation. 1993;88(suppl I):I-201. Abstract.
20. Théroux P, White H, David D, Van de Werf F, Nienaber CA, Charbonnier B, Erhardt L, Gill J, Hillis WS, Jennings G, Tan L-B, Deschenes N, Fitzpatrick V, Sax FL. A heparin-controlled study of MK-383 in unstable angina. Circulation. 1994;90(suppl I):I-231. Abstract.
21. Margolin BH. Test for trend in proportions. In: Johnson N, Kotz S, eds. Encyclopedia of Statistical Sciences. New York, NY: John Wiley & Sons; 1988:334-336.
22. Nam J. A simple approximation for calculating sample sizes for detecting linear trends in proportions. Biometrics. 1987;43:701-705.
23. Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G, Rosenberg M, Donohue TJ, Weisman HF, Califf RM, for the EPIC Investigators. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation. 1995;91:2882-2890.
24. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT, on behalf of the EPIC Investigators. Randomized trial of coronary intervention with antibody against IIb/ IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
25. Moise A, Théroux P, Taeymans Y, Descoings B, Lespérance J, Waters DD, Pelletier GB, Bourassa MG. Unstable angina and progression of atherosclerosis. N Engl J Med. 1983;309:685-689.
26. Willerson JT, Yao SK, McNatt J, Benedict CR, Anderson HV, Golino P, Murphree SS, Buja LM. Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury. Proc Natl Acad Sci USA. 1991;88:10624-10628.
27. Théroux P, Angiographic and clinical progression in unstable angina: from clinical observations to clinical trials. Circulation. 1995;91:2295-2298.